Research progress of targeted therapy combined with immunotherapy for hepatocellular carcinoma

Area of Science:

• Hepatology
• Oncology
• Immunology

Background:

• Hepatocellular carcinoma (HCC) is a prevalent gastrointestinal cancer with poor prognosis.
• Limited efficacy and high mortality characterize current HCC treatment options.
• Emerging therapies focus on combination strategies for improved outcomes.

Purpose of the Study:

• To review the research progress of combining molecular-targeted drugs with immune checkpoint inhibitors for HCC treatment.
• To discuss the efficacy and safety of this combination therapy.
• To provide a clinical reference for the application of these combined treatments.

Main Methods:

• Literature review of studies on molecular-targeted drugs and immune checkpoint inhibitors in HCC.
• Analysis of clinical trial data regarding combination therapy outcomes.
• Evaluation of safety profiles and adverse events associated with combined treatments.

Main Results:

• Combination therapy demonstrates significant survival benefits compared to single-agent treatments.
• Molecular-targeted drugs and immune checkpoint inhibitors show synergistic effects in HCC.
• The combination exhibits a manageable safety profile, though specific toxicities require monitoring.

Conclusions:

• Combining molecular-targeted drugs with immune checkpoint inhibitors represents a promising therapeutic strategy for hepatocellular carcinoma.
• This approach offers enhanced efficacy and prolonged survival for HCC patients.
• Further research and clinical application are warranted to optimize treatment protocols and patient selection.